A team of Israeli scientists is claiming that it has developed a medication that has the power to cure all types of cancer.
“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Dan Aridor, chairman of the board of Accelerated Evolution Biotechnologies Ltd. (AEBi), told The Jerusalem Post. “Our solution will be both generic and personal.”
In many ways, this sounds too good to be true, not least because cancer is the second leading cause of death worldwide. According to the World Health Organization, almost 10 million people died from the disease in 2018 alone. Still, despite these frightening statistics, the team of experts believe that their drug, MuTaTo, or multi-target toxin, has the power to eradicate cancer for good.
According to its creators, MuTaTo functions as a “cancer antibiotic,” using a combination of cancer-targeting peptides (amino acid chains) and also containing a toxin that specifically kills cancer cells. Through this breakthrough, the scientists believe they have created a blanket cure that can target cancer cells even after they have mutated into a different form. This, they say, is something that conventional cancer medication cannot achieve.
“We made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer,” explained AEBi CEO, Dr. Ilan Morad.
“The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used,” he continued. “Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.”
Morad noted that cancer cell mutations mean that the disease can appear as if it has been killed off, before returning with a vengeance.
“If it does not completely annihilate the cancer, the remaining cells can start to get mutations again, and then the cancer comes back, but this time it is drug resistant,” the doctor explained.
MuTaTo, he added, is very different in this regard. The drug can, according to its makers, destroy stem cells and reach diseased tissues previously impossible to target.
“This should make the whole molecule non-immunogenic in most cases and would enable repeated administration of the drug,” the specialist added.
Another aspect of the drug that has excited many in the scientific community is the claim that it will not cause the severe side effects experienced by patients undergoing conventional treatments. Morad noted that ghastly physical side-effects of these medicines are experienced as a result of the drugs interacting with the wrong or additional targets, often wiping out healthy, non-cancerous cells.
The targeted approach of MuTaTo, the team says, makes it uniquely effective.
According to CBN News, the MuTaTo is also a “personalized drug” meaning that cancer patients simply submit a biopsy to the lab, allowing the team of expert scientists to analyze it and “give the patient a personalized cocktail of MuTaTo that will specifically destroy their particular cancer.”
The team has already conducted successful tests on mice using their breakthrough drug, which “inhibited human cancer cell growth and had no effect at all on healthy mice cells.”
“Our results are consistent and repeatable,” Aridor concluded. “We believe we will offer in a year’s time a complete cure for cancer.”